<?xml version="1.0" encoding="UTF-8"?>
<p>One such novel design is based on prevention of recurrent TB disease in recently cured TB patients since this population is at an elevated risk of developing TB compared to individuals that have never had TB, due either to reinfection or to reactivation of existing infection. While a PoR endpoint could serve as a licensable indication in its own right, it currently is also being assessed as a possible means of de-risking a decision to move a vaccine candidate forward into late-stage PoD evaluations in the general population 
 <sup>
  <xref rid="ref-9" ref-type="bibr">9</xref>, 
  <xref rid="ref-10" ref-type="bibr">10</xref>
 </sup>.
</p>
